VivoSense Releases Newest Enhanced Wearable Sensor Analysis Platform

NEWPORT COAST, Calif., June 19, 2018 /PRNewswire/ -- VivoSense (Vivonoetics), the leading provider of visualization and analysis software for data from wearable sensors is excited to announce the release of VivoSense®️ 3.2.

With the accelerating adoption of wearable physiological sensors, large complex clinical trial data sets are being generated across a wide variety of patient populations and disease states, including rare diseases.

VivoSense® 3.2 provides the most rigorous analyses of these data possible in providing the endpoints and biomarkers which withstand Regulatory scrutiny and academic oversight.

As a company VivoSense is committed to providing robust clinical endpoints for industry leading biotechnology, pharma, CROs and healthcare providers including Roche, Mayo Clinic, Nationwide Children's Hospital and Harvard University.

Contact: Dudley Tabakin – [email protected] (949.933.3429)  

SOURCE VivoSense